Twist Bioscience Corporation
NASDAQ Global SelectTotal Valuation
Twist Bioscience Corporation carries a market capitalization of 8.01B, placing it among publicly traded companies globally. Its enterprise value stands at 6.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.01B |
| Enterprise Value | 6.37B |
Share Statistics
Twist Bioscience Corporation currently has 62.67M shares outstanding.
| Shares Outstanding | 62.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 14.63, and the price-to-book ratio stands at 14.47.
| PE Ratio | N/A |
| PS Ratio | 14.63 |
| PB Ratio | 14.47 |
| P/TBV Ratio | 18.38 |
| P/FCF Ratio | -485.14 |
| P/OCF Ratio | -119.03 |
Enterprise Valuation
| EV / Sales | 14.76 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Twist Bioscience Corporation maintains a current ratio of 2.67, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.67 |
| Quick Ratio | 2.12 |
| Debt / Equity | 21.00 |
| Debt / EBITDA | -0.83 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -29.59 |
| Return on Assets (ROA) | -20.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.79 |
Taxes
| Income Tax | 864,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Twist Bioscience Corporation's stock has gained approximately 402.18494% over the past 52 weeks. The 50-day moving average sits at 109.61, while the 200-day moving average is 63.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | 402.18494% |
| 50-Day Moving Average | 109.61 |
| 200-Day Moving Average | 63.75 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Twist Bioscience Corporation generated 431.80M in revenue and converted that into -136.72M in net income, yielding earnings per share of -2.23. EBITDA reached -112.58M, while operating income came in at -137.97M.
| Revenue | 431.80M |
| Gross Profit | 224.39M |
| Operating Income | -137.97M |
| Pretax Income | -135.85M |
| Net Income | -136.72M |
| EBITDA | -112.58M |
| EBIT | -137.97M |
| Earnings Per Share (EPS) | -2.23 |
Balance Sheet
Twist Bioscience Corporation holds 166.84M in cash and equivalents against 93.59M in total debt, resulting in a net debt position of -117.44M. Total book value stands at 445.74M, with working capital of 201.04M providing operational flexibility.
| Cash & Cash Equivalents | 166.84M |
| Total Debt | 93.59M |
| Net Debt | -117.44M |
| Equity (Book Value) | 445.74M |
| Book Value Per Share | 7.11 |
| Working Capital | 201.04M |
Cash Flow
Twist Bioscience Corporation produced -53.07M in operating cash flow over the past twelve months. After subtracting -40.05M in capital expenditures, free cash flow totaled -93.12M - equivalent to -1.52 per share.
| Operating Cash Flow | -53.07M |
| Capital Expenditures | -40.05M |
| Free Cash Flow | -93.12M |
| FCF Per Share | -1.52 |
Margins
Twist Bioscience Corporation operates with a gross margin of 51.97, reflecting its pricing power and cost economics. The operating margin of -31.95 and net profit margin of -31.66 provide insight into operational efficiency.
| Gross Margin | 51.97 |
| Operating Margin | -31.95 |
| Pretax Margin | -31.46 |
| Profit Margin | -31.66 |
| EBITDA Margin | -26.07 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.21 |
| FCF Yield | -0.21 |
Scores
Twist Bioscience Corporation posts an Altman Z-Score of 13.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.98 |